Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIENCY)

 v2.3.0.11
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIENCY) (USD $)
Common Stock
Advance Under Equity Financing
Additional Paid-in Capital
Deficit Accumulated During the Development Stage
Total
Balance at Aug. 09, 2005 $ 0 $ 0 $ 0 $ 0 $ 0
Balance (in shares) at Aug. 09, 2005 0        
Shares issued to founding stockholder 1,902 0 (402) 0 1,500
Shares issued to founding stockholder (in shares) 19,021,786        
Net loss 0 0 0 (16,124) (16,124)
Balance at Dec. 31, 2005 1,902 0 (402) (16,124) (14,624)
Balance (in shares) at Dec. 31, 2005 19,021,786        
Shares issued in connection with reverse merger transaction 401 0 62,099 0 62,500
Shares issued in connection with reverse merger transaction (in shares) 4,005,177        
Shares issued in private placements, net of offering costs 355 0 969,017 0 969,372
Shares issued in private placements, net of offering costs (in shares) 3,555,220        
Stock-based compensation costs 0 0 97,400 0 97,400
Net loss 0 0 0 (562,084) (562,084)
Balance at Dec. 31, 2006 2,658 0 1,128,114 (578,208) 552,564
Balance (in shares) at Dec. 31, 2006 26,582,183        
Shares issued in private placements, net of offering costs 100 0 531,220 0 531,320
Shares issued in private placements, net of offering costs (in shares) 999,995        
Stock-based compensation costs 25 0 890,669 0 890,694
Stock-based compensation costs (in shares) 250,000        
Stock-based research and development costs 0 0 50,836 0 50,836
Net loss 0 0 0 (1,648,488) (1,648,488)
Balance at Dec. 31, 2007 2,783 0 2,600,839 (2,226,696) 376,926
Balance (in shares) at Dec. 31, 2007 27,832,178        
Stock-based compensation costs 0 0 357,987 0 357,987
Stock-based research and development costs 10 0 213,051 0 213,061
Stock-based research and development costs (in shares) 100,000        
Net loss 0 0 0 (1,271,522) (1,271,522)
Balance at Dec. 31, 2008 2,793 0 3,171,877 (3,498,218) (323,548)
Balance (in shares) at Dec. 31, 2008 27,932,178        
Shares issued in private placements, net of offering costs 242 0 1,096,808 0 1,097,050
Shares issued in private placements, net of offering costs (in shares) 2,420,000        
Advance under equity financing 0 1,200,000 0 0 1,200,000
Stock-based compensation costs 15 0 745,965 0 745,980
Stock-based compensation costs (in shares) 150,000        
Stock-based research and development costs 0 0 132,933 0 132,933
Net loss 0 0 0 (1,551,333) (1,551,333)
Balance at Dec. 31, 2009 3,050 1,200,000 5,147,583 (5,049,551) 1,301,082
Balance (in shares) at Dec. 31, 2009 30,502,178        
Shares issued in private placements, net of offering costs 458 (1,200,000) 2,287,042 0 1,087,500
Shares issued in private placements, net of offering costs (in shares) 4,575,000        
Stock-based compensation costs 0 0 160,712 0 160,712
Stock-based research and development costs 0 0 67,222 0 67,222
Net loss 0 0 0 (880,250) (880,250)
Balance at Dec. 31, 2010 3,508 0 7,662,559 (5,929,801) 1,736,266
Balance (in shares) at Dec. 31, 2010 35,077,178        
Exercise of stock options 18 0 4,982 0 5,000
Exercise of stock options (in shares) 181,964        
Stock-based compensation costs 0 0 40,528 0 40,528
Stock-based research and development costs 0 0 982 0 982
Net loss 0 0 0 (698,768) (698,768)
Balance at Jun. 30, 2011 $ 3,526 $ 0 $ 7,709,051 $ (6,628,569) $ 1,084,008
Balance (in shares) at Jun. 30, 2011 35,259,142